Comparing two once-weekly diabetes medicines for blood sugar control
Treatments studied
Part of Hormones & metabolism clinical trials.
This study compares two newer once-weekly injectable medicines to see which one works better for lowering blood sugar in people with type 2 diabetes. You may join if your blood sugar is not well controlled on your current diabetes pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and your HbA1c (a measure of blood sugar over the past 3 months) is between 7.5% and 10.5%.
- You take metformin (a common diabetes pill) at a dose of at least 1500 mg per day (or the highest dose you can handle), with or without another diabetes medicine called an SGLT-2 inhibitor, for at least 3 months before starting the study.
- Your body mass index (BMI) is 25 or higher, which means you are considered overweight or obese.
- You do not have type 1 diabetes, and you have not had a serious complication like diabetic ketoacidosis or a hyperosmolar state.
- You do not have current or planned treatment for diabetic eye disease (retinopathy or macular edema), and you do not have a history of severe diabetic eye disease.
- You have not had a severe low blood sugar event in the last 6 months, and you can recognize symptoms of low blood sugar.
- Your weight has been stable (did not change by more than 5%) in the last 3 months.
- You have not had weight loss surgery (and do not plan to during the trial), except for liposuction or abdominoplasty over a year ago, or certain procedures that were removed over a year ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This study tests a new weekly injection (called NNC0487-0111) against an existing medicine (semaglutide) to see if it helps people with type 2 diabetes lose more weight. Together with standard diabetes care and lifestyle changes, you would receive the study medicine for about a year, and the study team will monitor your health and weight.
This study compares two injectable medications, RAY1225 and semaglutide, added to your usual diabetes pills, to see how well they control blood sugar and affect weight. It aims to help improve glucose control in people with type 2 diabetes.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.